In this initial study, the only patient who did not normalize CXCR4 expression levels also failed to increase CD4+ T cell counts after IL-2 treatment and did not benefit clinically from the therapy, with continued occurrence of multiple opportunistic infections. This evidence concerns the gene CXCR4 and Opportunistic infection.